These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 35172694)
21. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
22. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine. Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955 [TBL] [Abstract][Full Text] [Related]
23. Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy). Basso P; Negro C; Cegolon L; Larese Filon F Viruses; 2022 Feb; 14(2):. PubMed ID: 35215930 [No Abstract] [Full Text] [Related]
24. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data. Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923 [TBL] [Abstract][Full Text] [Related]
26. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM Front Immunol; 2021; 12():742914. PubMed ID: 34659237 [TBL] [Abstract][Full Text] [Related]
27. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers. Soysal A; Gönüllü E; Karabayır N; Alan S; Atıcı S; Yıldız İ; Engin H; Çivilibal M; Karaböcüoğlu M Hum Vaccin Immunother; 2021 Nov; 17(11):3876-3880. PubMed ID: 34324409 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis. Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977 [TBL] [Abstract][Full Text] [Related]
29. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022. Mweso O; Simwanza J; Malambo W; Banda D; Fwoloshi S; Sinyange N; Yoo YM; Feldstein LR; Kapina M; Mulenga LB; Liwewe MM; Musonda K; Kapata N; Mwansa FD; Agolory S; Bobo P; Hines J; Chilengi R BMJ Open; 2023 Dec; 13(12):e072144. PubMed ID: 38072491 [TBL] [Abstract][Full Text] [Related]
30. Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Soegiarto G; Wulandari L; Purnomosari D; Dhia Fahmita K; Ikhwan Gautama H; Tri Hadmoko S; Edwin Prasetyo M; Aulia Mahdi B; Arafah N; Prasetyaningtyas D; Prawiro Negoro P; Rosita Sigit Prakoeswa C; Endaryanto A; Gede Agung Suprabawati D; Tinduh D; Basuki Rachmad E; Astha Triyono E; Wahyuhadi J; Budi Keswardiono C; Elyana Wardani F; Mayorita F; Kristiani N; Baskoro A; Fetarayani D; Kartika Nurani W; Oceandy D Vaccine; 2022 Jun; 40(30):4046-4056. PubMed ID: 35660034 [TBL] [Abstract][Full Text] [Related]
31. COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort study. Almufty HB; Mamani MMA; Ali AH; Merza MA J Med Virol; 2022 Nov; 94(11):5244-5250. PubMed ID: 35811398 [TBL] [Abstract][Full Text] [Related]
32. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study. Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517 [No Abstract] [Full Text] [Related]
33. Effectiveness of four vaccines in preventing SARS-CoV-2 infection in Almaty, Kazakhstan in 2021: retrospective population-based cohort study. Nabirova D; Horth R; Smagul M; Nukenova G; Yesmagambetova A; Singer D; Henderson A; Tsoy A Front Public Health; 2023; 11():1205159. PubMed ID: 37351091 [TBL] [Abstract][Full Text] [Related]
34. Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile. Barrera-Avalos C; Luraschi R; Acuña-Castillo C; Vidal M; Mella-Torres A; Inostroza-Molina A; Vera R; Vargas S; Hernández I; Perez C; Vallejos-Vidal E; Valdés D; Imarai M; Reyes-López FE; Sandino AM Front Public Health; 2022; 10():797569. PubMed ID: 35387187 [TBL] [Abstract][Full Text] [Related]
35. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study. Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311 [TBL] [Abstract][Full Text] [Related]
36. Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile. Díaz-Dinamarca DA; Díaz P; Barra G; Puentes R; Arata L; Grossolli J; Riveros-Rodriguez B; Ardiles L; Santelises J; Vasquez-Saez V; Escobar DF; Soto D; Canales C; Díaz J; Lamperti L; Castillo D; Urra M; Zuñiga F; Ormazabal V; Nova-Lamperti E; Benítez R; Rivera A; Cortes CP; Valenzuela MT; García-Escorza HE; Vasquez AE Front Public Health; 2023; 11():1229045. PubMed ID: 37693706 [TBL] [Abstract][Full Text] [Related]
37. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study. Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735 [TBL] [Abstract][Full Text] [Related]
38. Characteristics of health care workers with SARS-CoV-2 at a COVID-19 hospital in Türkiye: Homologous versus heterologous vaccination. Alıravcı ID; Ertekin YH; Can G; Alkan S Pak J Med Sci; 2024 Sep; 40(8):1702-1708. PubMed ID: 39281253 [TBL] [Abstract][Full Text] [Related]
39. Determination of COVID-19 PCR positivity and mutation status in coronaVac vaccinated individuals in Turkey. Çalışkan A; Seçme M; Kalelı İ; Sarı T; Öner SZ; Yakın SK; Dönmez B Turk J Med Sci; 2022 Jun; 52(3):541-546. PubMed ID: 36326342 [TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcomes of healthcare workers with COVID-19 pre- and postvaccination. Filho FFD; Chaves EBM; D'Avila KG; Neyeloff JL; Dos Santos RP; Silva DR J Med Virol; 2022 Nov; 94(11):5279-5283. PubMed ID: 35831246 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]